Effect of Time-of-Day Administration of Amilodipine/Valsartan on Hypertention Control

Comparison of morning vs. evening administration of Amlodipine/Valsartan in hypertensive patients at Loghman hospital

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20240131060872N1

Enrollment

100

Registered

2024-04-10

Start date

2024-04-03

Completion date

Unknown

Last updated

2024-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stage II hypertension according to ACC/AHA2017 definition. Essential (primary) hypertension

Interventions

Intervention 1: Intervention group1 :Recipient of Amlodipine/Valsartan medicine in the evening with a single dose of 160.5 or 80.5 (according to the conditions of each patient) from Dr. Abidi's compan

Eligibility

Sex/Gender

All

Age

35 Years to 75 Years

Inclusion criteria

Inclusion criteria: Age range between 35-75 Absence of underlying disease such as no renal diseases, no diabetes mellitus, and no cardiovascular diseases No previous history of hypertension treatment Consent to enter the study

Exclusion criteria

Exclusion criteria: Having renal diseases Having diabetes Mellitus Having cardiovascular diseases including ischemic, non-ischemic, and heart failure

Design outcomes

Primary

Measure	Time frame
The percentage of people who have systolic blood pressure above 140 and/or diastolic blood pressure above 90. Timepoint: Blood pressure measurement at the beginning of the study (before the start of the intervention), 14 days and 56 days after the start of receiving the combination drug Amilodipine/Valsartan. Method of measurement: Holter device for measuring blood pressure.	—

Secondary

Measure	Time frame
Ankle edema. Timepoint: After 14 days from the start of the study. Method of measurement: Questionnaire and physical examination.;Hyperkalemia. Timepoint: After 14 days from the start of the study. Method of measurement: Questionnaire and serum k test.;Acute kidney injury. Timepoint: After 14 days from the start of the study. Method of measurement: Questionnaire, physical examination, serum Cr, urea, and urine analysis (U/A).;Orthostatic vertigo. Timepoint: After 14 days from the start of the study. Method of measurement: Questionnaire and physical examination.	—

Measure

Time frame

Ankle edema. Timepoint: After 14 days from the start of the study. Method of measurement: Questionnaire and physical examination.;Hyperkalemia. Timepoint: After 14 days from the start of the study. Method of measurement: Questionnaire and serum k test.;Acute kidney injury. Timepoint: After 14 days from the start of the study. Method of measurement: Questionnaire, physical examination, serum Cr, urea, and urine analysis (U/A).;Orthostatic vertigo. Timepoint: After 14 days from the start of the study. Method of measurement: Questionnaire and physical examination.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMarjan Hadian

Shahid Beheshti University of Medical Sciences

marjan7437@gmail.com+98 21 5541 9005

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026